NEW YORK (GenomeWeb News) - Canadian biomarker developer Med BioGene has hired an investment advisory and financial services company and has granted some of its executives options to buy up to 560,000 common shares at Can$.34 ($.32) a share, the company said today.
 
The Vancouver, BC-based MBI said it has hired Peterson Capital, an investment, financial services, and communications firm, for a monthly cash rate and the option to buy up to 100,000 shares at Can$.34 a share.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.